Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 0.61 |
| ▸ | TPO | P07202 | 4/20 | 0.61 |
| ▸ | PDE4A | P27815 | 3/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288047 | 0.77 | MPO (0.62) | MPOTPOPDE4APDE4BPDE4C | |
| SCHEMBL1460860 | 0.76 | MPO (1.00) | MPOTPOPDE4APDE4BPDE4C | |
| SCHEMBL2286250 | 0.76 | MPO (0.77) | MPOTPOPDE4APDE4BPDE4C | |
| SCHEMBL1958885 | 0.76 | TSHR (0.52) | KMT2APNPCYP3A4ALDH1A1POLB | |
| SCHEMBL2285006 | 0.75 | MPO (0.61) | MPOTPOPDE4APDE4BPDE4C | |
| SCHEMBL31025321 | 0.75 | MPO (0.67) | MPOTPOPDE4APDE4BPDE4C | |
| SCHEMBL2278851 | 0.75 | MPO (0.67) | MPOTPOPDE4APDE4BPDE4C | |
| SCHEMBL2288691 | 0.74 | MPO (0.54) | MPOTPOPDE4APDE4BPDE4C | |
| SCHEMBL2287220 | 0.74 | MPO (0.62) | MPOTPOPDE4APDE4BPDE4C | |
| SCHEMBL2282109 | 0.73 | MPO (0.58) | MPOTPOPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | claimed |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2014-08-07 | — | — | US | claimed |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | claimed |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | claimed |
| JP-4649112-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| EP-2200616-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | AstraZeneca AB (SE) | 2010-06-30 | — | — | EP | claimed |
| WO-2009025618-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| CN-100379737-C | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-04-09 | — | — | CN | claimed |
| CN-101062037-A | Thioxanthine derivatives, process for their preparation (variants), their use and composition containing them | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | claimed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | claimed |
| JP-2005526836-A | — | — | 2005-09-08 | — | — | JP | claimed |
| CN-1646531-A | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | CN | claimed |
| EP-1499613-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | claimed |
| WO-2003089430-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | claimed |
| CN-113633641-A | MPO inhibitors for the treatment of huntington's disease and multiple system atrophy | 阿斯利康(瑞典)有限公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2021013942-A1 | USE OF MYELOPEROXIDASE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS SUFFERING FROM MYELOPROLIFERATIVE NEOPLASMS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-01-28 | — | — | WO | disclosed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | disclosed |
| CN-1646531-A | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885PDE4A 814/4885 |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | MPO, XDH, EPX | MPO 1/4885TPO 5/4885PDE4A 793/4885 |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885PDE4A 814/4885 |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | MPO, XDH, EPX | MPO 1/4885TPO 5/4885PDE4A 793/4885 |
| US-20090054468-A1 | New Use 938 | MPO, CAT, HTT | MPO 1/4885TPO 199/4885PDE4A 429/4885 |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885TPO 87/4885PDE4A 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.